Inhibition of lipid synthesis through activation of AMP kinase: an additional mechanism for the hypolipidemic effects of berberine

被引:291
作者
Brusq, Jean-Marie [1 ]
Ancellin, Nicolas [1 ]
Grondin, Pascal [1 ]
Guillard, Raphaelle [1 ]
Martin, Sandrine [1 ]
Saintillan, Yannick [1 ]
Issandou, Marc [1 ]
机构
[1] GlaxoSmithKline, F-91951 Les Ulis, France
关键词
low density lipoprotein cholesterol; PD98059; 5-aminoimidazole-4-carboxamide; 1-beta-ribofuranoside; fatty acid oxidation; phosphorylation of acetyl-coenzyme A carboxylase;
D O I
10.1194/jlr.M600020-JLR200
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The alkaloid drug berberine (BBR) was recently described to decrease plasma cholesterol and triglycerides (TGs) in hypercholesterolemic patients by increasing expression of the hepatic low density lipoprotein receptor (LDLR). Using HepG2 human hepatoma cells, we found that BBR inhibits cholesterol and TG synthesis in a similar manner to the AMP-activated protein kinase (AMPK) activator 5-aminoimidazole-4-carboxamide 1-beta-ribofuranoside (AICAR). Significant increases in AMPK phosphorylation and AMPK activity were observed when the cells were incubated with BBR. Activation of AMPK was also demonstrated by measuring the phosphorylation of acetyl-CoA carboxylase, a substrate of AMPK, correlated with a subsequent increase in fatty acid oxidation. All of these effects were abolished by the mitogen-activated protein kinase kinase inhibitor PD98059. Treatment of hyperlipidemic hamsters with BBR decreased plasma LDL cholesterol and strongly reduced fat storage in the liver. These findings indicate that BBR, in addition to upregulating the LDLR, inhibits lipid synthesis in human hepatocytes through the activation of AMPK. These effects could account for the strong reduction of plasma TGs observed with this drug in clinical trials.
引用
收藏
页码:1281 / 1288
页数:8
相关论文
共 26 条
[1]   Extracellular signal-regulated kinase-dependent stabilization of hepatic low-density lipoprotein receptor mRNA by herbal medicine berberine [J].
Abidi, P ;
Zhou, Y ;
Jiang, JD ;
Liu, JW .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2005, 25 (10) :2170-2176
[2]   Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[3]   Pharmacotherapy for dyslipidaemia - current therapies and future agents [J].
Bays, H ;
Stein, EA .
EXPERT OPINION ON PHARMACOTHERAPY, 2003, 4 (11) :1901-1938
[4]   A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with primary hypercholesterolemia [J].
Bays, HE ;
Ose, L ;
Fraser, N ;
Tribble, DL ;
Quinto, K ;
Reyes, R ;
Johnson-Levonas, AO ;
Sapre, A ;
Donahue, SR .
CLINICAL THERAPEUTICS, 2004, 26 (11) :1758-1773
[5]   ApoB-100 secretion by HepG2 cells is regulated by the rate of triglyceride biosynthesis but not by intracellular lipid pools [J].
Benoist, F ;
GrandPerret, T .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1996, 16 (10) :1229-1235
[6]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[7]   TISSUE DISTRIBUTION OF THE AMP-ACTIVATED PROTEIN-KINASE, AND LACK OF ACTIVATION BY CYCLIC-AMP-DEPENDENT PROTEIN-KINASE, STUDIED USING A SPECIFIC AND SENSITIVE PEPTIDE ASSAY [J].
DAVIES, SP ;
CARLING, D ;
HARDIE, DG .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1989, 186 (1-2) :123-128
[8]   Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS [J].
Downs, JR ;
Clearfield, M ;
Weis, S ;
Whitney, E ;
Shapiro, DR ;
Beere, PA ;
Langendorfer, A ;
Stein, EA ;
Kruyer, W ;
Gotto, AM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20) :1615-1622
[9]  
ENDO A, 1992, J LIPID RES, V33, P1569
[10]   The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways [J].
Fryer, LGD ;
Parbu-Patel, A ;
Carling, D .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2002, 277 (28) :25226-25232